Dr. Mills Discusses Assay of the Genome to Further Measure DNA and RNA
Gordon B. Mills, MD, PhD, The University of Texas MD Anderson Cancer Center, discusses assay of the genome in order to further measure DNA and RNA.
Mills says there is an incredible amount of new information arising from the cancer genome atlas, as well as similar programs in the academic community. Thus far, information has mostly focused on the DNA and RNA levels so far. Mills and his colleagues are investigating a protein-based analysis of the cancer genome.
This provides new information and opportunities that were not previously present, says Mills.
Gordon B. Mills, MD, PhD, professor of medicine and immunology, Olga Keith Wiess Distinguished University Chair for Cancer Research, co-director, Zayed Institute for Personalized Cancer Therapy, chair, Department of Systems Biology, Ann Rife Cox Chair in Gynecology, administrative director, Kleberg Center for Molecular Markers, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses assay of the genome in order to further measure DNA and RNA.
Acalabrutinib/Obinutuzumab Shows Improved PFS in Treatment-Naive CLL
April 10th 2024In an interview with Targeted Oncology, Jeff Sharman, MD, discussed the results of the ELEVATE-TN trial of acalabrutinib with or without obinutuzumab at 74.5 months of follow-up among patients with chronic lymphocytic leukemia.
Read More
